Liver Cancer Podcast

Liver Cancer Podcast

by International Liver Cancer Association (ILCA)

Non-Profit Education Medicine

Season 2

Selected abstracts of the Liver Cancer Summit 2022 of EASL

Download full transcript here In this podcast, Alejandro Forner summarised and commented some selected abstracts at the EASL Liver Cancer Summit 2022. The following abstracts will be discussed: 1. Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Exploratory analysis of safety and overall survival in the prospective, observational REFINE study. Finn R, et al. Liver Cancer Summit 2022 OS-55 2. Efficacy of combination therapy with lenvatinib, programmed cell death 1 inhibitors and transarterial therapy: a propensity score-matching cohort study. Wei Lu, et al. Liver Cancer Summit 2022 PO-119 3. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study.Thomas Talbot, et al. Liver Cancer Summit 2022 PO-128 4. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma. Elia Gigante et al. Liver Cancer Summit 2022 PO-148 5. Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with advanced hepatocellular carcinoma: A real-world, multicentre, retrospective study. Guohong Han et al. Liver Cancer Summit 2022 PO-220 6. Liver transplantation for combined hepatocellular-cholangiocarcinoma: An analysis of the European Liver Transplant Registry. Marco Claasen et al. Liver Cancer Summit 2022 PO-308 7. Liver transplantation for fibrolamellar hepatocellular carcinoma: An analysis of the European Liver Transplant Registry. Marco Claasen et al. Liver Cancer Summit 2022 PO-313

Phase 3 data from ESMO and ASCO GI

In this Podcast Drs. Richard Finn and Mark Yarchoan review recent practice changing data from recent international meetings including ESMO Asia 2021 and ASCG GI 2022. These include results of the COSMIC 312 study, the HIMALAYA study, KEYNOTe 394 among others. Please join us for data review and some comments to put these results in context.

Design of Clinical Trials for Adjuvant and Locoregional Strategies

Read the full transcript here. In this podcast, co-chairs Lorenza Rimassa and Pierre Nahon summarised and commented the presentations during the plenary session Design of Clinical Trials for Adjuvant and Locoregional Strategies at the EASL Liver Cancer Summit 2022. Speakers: · Lorenza Rimassa, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy · Pierre Nahon, Avicenne Hospital in Bondy, APHP, France

Latest Data in Systemic Therapy for Liver Cancer

Download episode transcript here In this podcast, co-chairs Jens Marquardt and Lorenza Rimassa summarised and commented the presentations during the session Latest Data in Systemic Therapy for Liver Cancer at the EASL Liver Cancer Summit 2022. · The session aim to provide an overview on the latest developments in systemic therapies for primary liver cancer · The session will discuss the relevance of precision oncological as well as immune-oncological approaches in HCC and CCA · The session will delineate future concepts and strategies for primary liver cancer Speakers: · Jens Marquardt, University of Lübeck, Germany · Lorenza Rimassa, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

Season 1

Therapy & Clinical Trials in 2021

Download full transcript here In this podcast, Lorenza Rimassa and Alejandro Forner summarised and commented the six abstracts orally presented during the General Session 4: Therapy & Clinical Trials in 2021 at the ILCA Annual Conference 2021. Speakers: · Lorenza Rimassa, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy · Alejandro Forner, BCLC Group, Barcelona, Spain

Diagnosis, Imaging and Biomarkers in 2021

In this podcast, co-chairs Amit Singal and Nicole Rich summarised and commented the abstracts orally presented during the General Session 3: Diagnosis, Imaging and Biomarkers at the ILCA Annual Conference 2021. Speakers: · Amit Singal, MD, UT Southwestern Medical Center, USA · Nicole Rich, MD, MSCS, UT Southwestern Medical Center, USA

Epidemiology, Staging and Prognosis in 2021

In this podcast, co-chairs David Pinato and Anjana Pillai summarised and commented the abstracts orally presented during the General Session 2: Epidemiology, Staging and Prognosis at the ILCA Annual Conference 2021. Speakers: · David Pinato, Clinical Senior Lecturer in Medical Oncology, Imperial College London · Anjana Pillai, Associate Professor of Medicine, University of Chicago Medicine

Molecular Pathogenesis, Cell Biology and Translational Research in 2021

Download full transcript here In this podcast, co-chairs Amaia Lujambio and Stephanie Roessler summarised and commented the abstracts orally presented during the General Session 1: Molecular Pathogenesis, Cell Biology and Translational Research at the ILCA Annual Conference 2021. Speakers: · Amaia Lujambio, Icahn School of Medicine at Mount Sinai, New York · Stephanie Roessler, University of Heidelberg, Germany

3 of 3